Centene (CNC) Set to Post Earnings on Tuesday

Centene (NYSE:CNC) is expected to announce its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to post earnings of $0.0956 per share and revenue of $47.11 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

Centene (NYSE:CNC) last announced its quarterly earnings results on Monday, July 27th. The company reported $2.51 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $1.42. Centene had a positive return on equity of 12.12% and a negative net margin of 2.51%. The firm had revenue of $53.58 billion for the quarter, compared to analysts’ expectations of $47.64 billion. During the same period in the prior year, the business posted ($0.16) earnings per share. The business’s revenue was up 9.9% compared to the same quarter last year. On average, analysts expect Centene to post $4.89 EPS for the current fiscal year and $5.34 EPS for the next fiscal year.

Centene Stock Performance

Centene stock opened at $68.59 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.15 and a quick ratio of 1.15. The stock has a fifty day moving average price of $65.46 and a two-hundred day moving average price of $60.12. Centene has a 52-week low of $31.63 and a 52-week high of $71.21. The firm has a market capitalization of $33.88 billion, a P/E ratio of 13.33, a P/E/G ratio of 0.44 and a beta of 1.13.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Centene from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Robert W. Baird increased their target price on shares of Centene from $46.00 to $66.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. increased their target price on shares of Centene from $60.00 to $67.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Royal Bank Of Canada lifted their price target on shares of Centene from $70.00 to $71.00 and gave the company a “sector perform” rating in a report on Thursday, July 9th. Finally, Stifel Nicolaus set a $79.00 price target on shares of Centene in a research report on Monday, August 3rd. Nine investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $70.05.

Insiders Place Their Bets

In related news, General Counsel Christopher Koster sold 56,500 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $66.90, for a total transaction of $3,779,850.00. Following the completion of the sale, the general counsel directly owned 248,854 shares of the company’s stock, valued at $16,648,332.60. This trade represents a 18.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.37% of the stock is owned by corporate insiders.

Centene Company Profile

Centene Corporation is a diversified healthcare enterprise that provides government-sponsored and commercial health insurance programs and related healthcare services. The company’s offerings are primarily focused on Medicaid, Medicare, and health insurance marketplace plans, with an emphasis on serving individuals and families who may have limited access to traditional healthcare coverage.

Centene operates Medicaid health plans through state-based contracts and offers Medicare Advantage, Medicare prescription drug, and Medicare Supplement products through its Wellcare brand.